Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies
| Autor: | Victor L. Villemagne, Shaun Frost, Prita R. Asih, Kevin Taddei, James D. Doecke, Eugene Hone, Samantha C. Burnham, Kathryn A. Ellis, Giuseppe Verdile, Ralph N. Martins, Veer Bala Gupta, Simon M. Laws, Olivier Salvado, David Ames, Ian Martins, Pratishtha Chatterjee, Wei Ling Lim, Christopher C. Rowe, Sunil Gupta, Eka J. Wahjoepramono, Tejal M. Shah, Belinda M. Brown, Sam Gandy, Kathryn Goozee, Sid E. O'Bryant, Colin L. Masters, Paul E. Fraser, Binosha Fernando, Alan Rembach, Steve Pedrini, Prashant Bharadwaj, Samantha L. Gardener, Stephanie R. Rainey-Smith, Stephanie J. Fuller, Hamid R. Sohrabi, Ashley I. Bush, Anna M. Barron |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Gerontology Apolipoprotein E Amyloid Amyloidogenic Proteins Review Disease 03 medical and health sciences 0302 clinical medicine Alzheimer Disease preclinical medicine Animals Humans Dementia Cognitive decline Aβ apolipoprotein E business.industry General Neuroscience Australia amyloid General Medicine medicine.disease Oxidative Stress Psychiatry and Mental health Clinical Psychology 030104 developmental biology biomarker Biomarker (medicine) Geriatrics and Gerontology Alzheimer's disease business Alzheimer’s disease Biomarkers 030217 neurology & neurosurgery dementia early diagnosis Cohort study |
| Zdroj: | Journal of Alzheimer's Disease |
| ISSN: | 1875-8908 1387-2877 |
| DOI: | 10.3233/jad-171145 |
| Popis: | Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-β peptide (also known as Aβ or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the journey from the discovery of the Aβ peptide in Alzheimer’s disease (AD) brain to the establishment of pre-clinical AD using PET amyloid tracers, a method now serving as the gold standard for developing peripheral diagnostic approaches in the blood and the eye. The latter developments for early diagnosis have been largely achieved through the establishment of the Australian Imaging Biomarker and Lifestyle research group that has followed 1,100 Australians for 11 years. AIBL has also been instrumental in providing insight into the role of the major genetic risk factor apolipoprotein E ɛ4, as well as better understanding the role of lifestyle factors particularly diet, physical activity and sleep to cognitive decline and the accumulation of cerebral Aβ. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|